News

The federal agency's decision makes this the first CMV treatment for this patient population.

In its first real-world study, 2 doses of India’s BBV152 vaccine offered 50% protection against symptomatic COVID-19.

The Scynexis ibrexafungerp (Brexafemme) therapy cleared signs and symptoms of vaginal yeast infection in 73.9% of patients.

This infection has the ability to remain undetected and the potential to spread very quickly in long-term care facilities and hospitals.

The Infectious Diseases Society of America (IDSA) released new expert-informed guidelines for treating antimicrobial-resistant AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections.

Researchers shared an update on progress made towards regional measles elimination across the world for the past twenty years.

A study found trans people were not substantively included in many countries’ HIV national strategic plans, despite being disproportionately impacted by HIV/AIDS.

Weekly Arakoda for malaria prevention was found safe and tolerable for healthy adults who travel internationally.

The report on antimicrobial resistance finds new therapeutics are "essential to future of clinical medicine" but may not be viable in present market.

Routine infant, child, and adolescent vaccination rates and coverage were lower in 2020 than in 2019, particularly for Black children.

Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.

The report assesses progress of a US national action plan to combat antimicrobial resistance, called for by 2015 World Health Assembly.

From its origins as a serendipitous discovery to being successfully prescribed for nearly a century, antibiotics remain a foundation of medicine. However it has major ongoing challenges including the rise of superbugs and the development of antimicrobial resistance (AMR). There are some prospective strategies to combat AMR on the horizon.

The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.

Providers and key stakeholders weigh in on this significant topic.

The European Center for Diseases Prevention and Control published data today showing the greatest decrease in antibiotic consumption in 2 decades coincided with the COVID-19 pandemic.

AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.

In the second installment discussing this report, the authors point out that the approval of new diagnostics can help facilitate better stewardship.

The National Academies report reviews several challenges, and ways to overcome them for optimal antimicrobial stewardship.

Retesting positive COVID-19 PCR tests from asymptomatic, nonexposed persons and tests stored next to a specimen with high viral load identified false positives.

The National Academy of Medicine released 4 reports with COVID-19-influenced recommendations to prepare and respond to an influenza pandemic.

CEO Christopher Burns spoke about their investigational therapy pipeline, the long view perspective for the company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.

A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.

Investigators analyzed data from COVID-NET across 14 states as this variant quickly become the dominant strain within the United States.

Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.

States with policy that permitted adolescents to independently choose to receive HPV vaccination had a significantly higher immunization uptake.

This agreement with the Medicines Patient Pool (MPP) would allow licensing of the company’s antiviral treatment candidate, PF-07321332, internationally to numerous countries.

Betsy Wonderly-Trainor discusses CARB-X's mission to fund novel antibiotics, preventatives, and diagnostics in the fight against antimicrobial resistance.